Lamia Y. K. Haque, MD, MPH
Assistant Professor of Medicine (Digestive Diseases)Cards
About
Research
Publications
2024
Using Phosphatidylethanol as an Adjunct to Self-Reported Alcohol Use Improves Identification of Liver Fibrosis Risk.
Murnane P, Afshar M, Chamie G, Cook R, Ferguson T, Haque L, Jacobson K, Justice A, Kim T, Khalili M, Krupitsky E, McGinnis K, Molina P, Muyindike W, Myers B, Richards V, So-Armah K, Stewart S, Sulkowski M, Tien P, Hahn J. Using Phosphatidylethanol as an Adjunct to Self-Reported Alcohol Use Improves Identification of Liver Fibrosis Risk. The American Journal Of Gastroenterology 2024 PMID: 39480054, DOI: 10.14309/ajg.0000000000003178.Peer-Reviewed Original ResearchLiver fibrosis riskAUDIT-CFIB-4Self-reported alcohol useOdds ratioAlcohol useFibrosis riskPooled individual-level dataLiver fibrosis preventionBody mass indexAssessment of alcohol useManagement of liver diseaseOne-unit differenceIndividual-level dataMedian ageAUDIT-C.Mass indexSuppression statusLiver diseaseFibrosis preventionBlood concentrationsAdjusted modelsLogistic regressionCategorical variablesHIVA Validated Algorithm to Identify Hepatic Decompensation in the Veterans Health Administration Electronic Health Record System
Haque L, Tate J, Chew M, Caniglia E, Taddei T, Re V. A Validated Algorithm to Identify Hepatic Decompensation in the Veterans Health Administration Electronic Health Record System. Pharmacoepidemiology And Drug Safety 2024, 33: e70024. PMID: 39477692, PMCID: PMC11631147, DOI: 10.1002/pds.70024.Peer-Reviewed Original ResearchConceptsVeterans Health Administration dataHealth administrative dataAdministrative dataElectronic health record systemsHealth record systemsInternational Classification of DiseasesCoding algorithmOutpatient International Classification of DiseasesPositive predictive valueClassification of DiseasesHepatic decompensationDiagnosis codesPharmacoepidemiologic researchMedical recordsVeteransRecording systemValidation algorithmAlgorithmChronic liver diseaseDecompensationLiver diseasePredictive valueRecordsDiagnosisEpidemiology and Health Care Burden of Alcohol Use Disorder
Choi H, Balter D, Haque L. Epidemiology and Health Care Burden of Alcohol Use Disorder. Clinics In Liver Disease 2024, 28: 577-588. PMID: 39362708, DOI: 10.1016/j.cld.2024.06.006.Peer-Reviewed Original ResearchW31 The Impact of Tobacco Use on Liver-Related Morbidity in Patients With Cirrhosis
Haque L, Fiellin D, Bryant K, Edelman E, Justice A, Lim J, Re V, Marshall B, Taddei T, Tate J, Tetrault J, Williams E, McGinnis K. W31 The Impact of Tobacco Use on Liver-Related Morbidity in Patients With Cirrhosis. Drug And Alcohol Dependence 2024, 260: 110649. DOI: 10.1016/j.drugalcdep.2023.110649.Peer-Reviewed Original ResearchIntegrated and collaborative care across the spectrum of alcohol-associated liver disease and alcohol use disorder.
Haque L, Leggio L. Integrated and collaborative care across the spectrum of alcohol-associated liver disease and alcohol use disorder. Hepatology 2024, 80: 1408-1423. PMID: 38935926, DOI: 10.1097/hep.0000000000000996.Peer-Reviewed Original ResearchAUD careAlcohol-associated liver diseaseAlcohol use disorderCollaborative careImpact of health disparitiesAlcohol-related deathsImpact of comorbid conditionsPublic health impactUse disorderHarm reduction approachesLiver diseaseInterprofessional teamHealth disparitiesTreatment of alcohol use disordersComprehensive careProblematic alcohol useSubstance use disordersSpectrum of alcohol-associated liver diseasesTreatment gapLiver-related outcomesMinority of patientsLiver-related morbidityAlcohol use disorder treatmentCareAlcohol useAddiction and liver disease series
Haque L, Mellinger J. Addiction and liver disease series. Clinical Liver Disease 2024, 23: e0227. PMCID: PMC11164010, DOI: 10.1097/cld.0000000000000227.Peer-Reviewed Original ResearchOpportunities for Alcohol-Related Care in the COVID-19 Pandemic and Beyond
Oldfield B, Haque L, Jennifer Edelman E. Opportunities for Alcohol-Related Care in the COVID-19 Pandemic and Beyond. Journal Of General Internal Medicine 2024, 39: 2129-2130. PMID: 38671202, PMCID: PMC11347542, DOI: 10.1007/s11606-024-08730-w.Peer-Reviewed Original ResearchFeasibility of an Interprofessional Inpatient Educational Intervention for Patients With Decompensated Cirrhosis
Haque L, McDonough M, Deng Y, Ciarleglio M, Liapakis A, Jakab S. Feasibility of an Interprofessional Inpatient Educational Intervention for Patients With Decompensated Cirrhosis. Gastro Hep Advances 2024, 3: 615-617. PMID: 39165423, PMCID: PMC11330928, DOI: 10.1016/j.gastha.2024.03.011.Peer-Reviewed Original ResearchManagement of alcohol-associated liver disease and alcohol use disorder in liver transplant candidates and recipients: Challenges and opportunities
Sharma P, Shenoy A, Shroff H, Kwong A, Lim N, Pillai A, Devuni D, Haque L, Balliet W, Serper M. Management of alcohol-associated liver disease and alcohol use disorder in liver transplant candidates and recipients: Challenges and opportunities. Liver Transplantation 2024, 30: 848-861. PMID: 38471008, DOI: 10.1097/lvt.0000000000000362.Peer-Reviewed Original ResearchAlcohol-associated liver diseaseAlcohol use disorderAUD careValue-based care modelsPrevalence of alcohol use disordersPost-LTLiver transplantationManagement of alcohol-associated liver diseasePost-transplant patient survivalLiver diseaseRisk of disease recurrenceUse disorderImprove patient outcomesPost-LT relapseCare modelSystemic barriersTherapy accessDigital healthUnmet needsLiver transplant candidatesAlcohol consumptionCenters of excellenceGlobal health burdenAddiction specialistsCareTreatment of alcohol use disorder in patients with alcohol-associated liver disease: Innovative approaches and a call to action
Haque L, Zuluaga P, Muga R, Fuster D. Treatment of alcohol use disorder in patients with alcohol-associated liver disease: Innovative approaches and a call to action. Addiction Science & Clinical Practice 2024, 19: 19. PMID: 38504384, PMCID: PMC10949674, DOI: 10.1186/s13722-024-00448-8.Peer-Reviewed Original ResearchConceptsAlcohol-associated liver diseaseAlcohol use disorderLiver diseasePresence of liver cirrhosisTreatment of alcohol use disordersUse disorderInnovative treatment strategiesUnhealthy alcohol usePharmacologic treatment choicesTreating unhealthy alcohol useLiver transplantationLiver cirrhosisTreatment strategiesTreatment choiceEfficacious treatmentLiver deathsPatientsAlcohol useDiseaseLiverTreatmentDisordersCirrhosisTransplantation
Academic Achievements & Community Involvement
Clinical Care
Overview
Lamia Haque, MD, MPH is a hepatologist (liver specialist) and addiction medicine physician who treats patients with liver diseases and co-occurring substance use disorders. She has additional training in transplant hepatology.
Dr. Haque says she was initially drawn to general internal medicine during medical school. “But after doing a few rotations with the hepatology service during residency at Yale, I felt it was a great fit. I became interested in the overlap between addiction and liver diseases, so I completed a fellowship in addiction medicine prior to my training in hepatology with the goal of integrating these skills into my work as a liver specialist,” she says.
“The main focus of my clinic is providing integrated care for patients who have both addiction and liver disease, particularly those with alcohol-associated liver disease and cirrhosis,” she says. “I find taking care of my patients to be very rewarding. You get to build a strong relationship over time.”
Because liver disease can be silent in its early stages, it can sometimes take patients by surprise if an abnormality shows up in their blood work or imaging.
“For patients with advanced liver disease and addiction, my work involves a lot of education and goal-setting. We work together to fine-tune medications, manage any complications that may arise, ensure that health maintenance measures are taken, determine the goals of care, and if indicated, set up a referral for a liver transplant evaluation,” says Dr. Haque. “Providing on-site addiction treatment and facilitating referrals as needed is an important part of delivering comprehensive care for patients with conditions such as alcohol-associated liver disease and alcohol use disorder.”
Dr. Haque’s research involves using implementation science methods to integrate evidence-based addiction treatment into liver care settings.
Clinical Specialties
Fact Sheets
Alcohol-related Liver Disease
Learn More on Yale MedicineRectal Bleeding
Learn More on Yale Medicine
Board Certifications
Transplant Hepatology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2022
Gastroenterology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2020
Obesity Medicine
- Certification Organization
- AB of Obesity Medicine
- Original Certification Date
- 2020
Addiction Medicine (Preventive Medicine)
- Certification Organization
- AB of Preventive Medicine
- Original Certification Date
- 2018
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2016
Yale Medicine News
News
News
- August 03, 2024
Addressing Behavioral Health in Patients With End-stage Liver Disease
- December 13, 2022
Patients With Alcohol Use Disorder Face Barriers to Lifesaving Hepatitis C Treatment, Study Finds
- May 26, 2022Source: YaleNews
Office Hours with… Lamia Haque
- October 14, 2021
Discoveries & Impact (October 2021)
Get In Touch
Contacts
Yale School of Medicine
Department of Medicine (Digestive Diseases), PO Box 208019
New Haven, CT 06520-8019
United States
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.